If you have spent any time in nootropic communities, you have almost certainly seen Semax and Selank mentioned together, usually by someone who describes them as "Russian government peptides" with an air of forbidden wisdom. That framing is not entirely wrong. Both compounds were developed in the Soviet Union, both are approved drugs in Russia for different indications, and both are sold on grey-market peptide sites in the West as cognitive enhancers. The honest question is: what does the actual evidence say, and does it justify the hype? The short answer is that both peptides have real, published science behind them, but that science is almost entirely preclinical or conducted under Russian regulatory standards that do not translate directly to FDA-recognized evidence — and that gap matters more than most vendors acknowledge.
Neither Semax nor Selank is FDA-approved in the United States for any indication.
Quick Summary
Semax is a synthetic fragment of adrenocorticotropic hormone (ACTH), developed in the 1980s and used clinically in Russia as a neuroprotective agent after stroke and traumatic brain injury. Its primary mechanism involves upregulating brain-derived neurotrophic factor (BDNF) and modulating gene expression in the ischemic brain.
Selank is a synthetic analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. It is registered in Russia as an anxiolytic and approved for anxiety and neurasthenia. Its primary mechanism involves positive allosteric modulation of GABA receptors, with additional effects on serotonin and enkephalin systems.
Neither compound has completed a large, double-blind, placebo-controlled trial meeting FDA or EMA evidentiary standards. Both are circulating in Western markets under the "research peptide" label, which has a specific legal meaning: they are not approved for human consumption, and sites selling them for self-experimentation are operating in a regulatory grey zone.
If you are experiencing cognitive decline, persistent anxiety, or neurological symptoms, see a neurologist or psychiatrist. Do not delay a proper diagnosis by experimenting with unregulated peptides.
What Is Semax?
Semax carries the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is derived from the ACTH 4-10 fragment, the stretch of adrenocorticotropic hormone that researchers identified as neurologically active rather than hormonally active. Soviet pharmacologists at the Institute of Molecular Genetics began working on it in the late 1970s, extending the core fragment with a Pro-Gly-Pro tail to improve stability and bioavailability. The resulting compound was approved in Russia for acute ischemic stroke, cognitive impairment, and optic nerve disease.
The pharmacological profile that generated the most research interest is Semax's effect on neurotrophins. A 2006 study (PMID 16996037) found that a single intranasal application of 50 micrograms per kilogram in rats produced a 1.4-fold increase in BDNF protein in the hippocampus and a 1.6-fold rise in trkB tyrosine phosphorylation — the receptor that BDNF activates. At the mRNA level, the effects were larger: BDNF mRNA tripled and trkB mRNA doubled compared to controls. BDNF is critical for synaptic plasticity and memory consolidation, which is why these findings attracted attention. The limitation is significant: this is an animal study, single-dose, with conditioned avoidance as the cognitive readout. Human pharmacokinetics and dosing are not established.
In stroke research, Semax's mechanism looks more immunological than purely neurotrophic. A 2014 genome-wide transcriptional analysis (PMID 24661604) found that after focal ischemia in rats, Semax predominantly enhanced expression of immune system genes, with immune-response genes comprising more than 50% of all altered transcripts at 24 hours. The researchers concluded that immunomodulation and vascular system regulation are likely the key mechanisms of its neuroprotective effect, rather than any single pathway.
A 2021 protein expression study (PMID 34201112) confirmed downstream molecular markers of this protection: Semax-treated animals showed increased CREB activation in subcortical structures, reduced MMP-9 levels in adjacent cortical tissue, and suppressed JNK signaling, indicating both reduced inflammation and reduced cell death. A companion transcriptome analysis (PMID 32580520) identified 394 differentially expressed genes in Semax-treated versus control animals, with inflammatory gene expression suppressed and neurotransmission gene expression activated.
Semax is typically administered intranasally in Russian clinical practice, at doses of 200 to 600 micrograms per day for acute indications.
What Is Selank?
Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic derivative of tuftsin, a tetrapeptide fragment of immunoglobulin G that naturally modulates immune function. Researchers extended the tuftsin sequence with a Pro-Gly-Pro tail — the same stabilizing addition used in Semax — to create a compound with both anxiolytic and immunomodulatory properties.
The Russian Ministry of Health registered Selank as a treatment for anxiety disorder and neurasthenia. Its clinical use in Russia centers on anxiety reduction without the sedation and dependence risk associated with benzodiazepines. That registration is real; it is also not the same as FDA approval, which requires independent replication under a separate, more demanding evidentiary framework.
Selank's primary anxiolytic mechanism operates through GABA receptor modulation. A 2018 study (PMID 30255741) using radioligand-receptor analysis demonstrated that Selank acts as a positive allosteric modulator of GABA receptors, enhancing GABA binding rather than directly activating the receptor. The same study found that Selank can block the modulatory activity of diazepam and olanzapine at the receptor level, suggesting partially overlapping binding sites. This is a nuanced finding: Selank is not simply a weaker benzodiazepine; it works at the same receptor family through a different mechanism.
A 2017 behavioral study (PMID 28280289) compared Selank alone, diazepam alone, and the combination in a chronic unpredictable mild stress model in rats. Selank alone was the most effective intervention for elevated baseline anxiety. Under chronic stress conditions, the diazepam-Selank combination outperformed either compound individually, suggesting synergistic GABAergic effects.
Selank also affects BDNF, though differently from Semax. A 2019 study (PMID 31625062) showed that Selank prevented ethanol-induced increases in BDNF content in the hippocampus and frontal cortex, and also prevented ethanol-induced memory and attention disturbances in rats. The researchers framed this as evidence of a regulatory effect on neurotrophin production during neurological stress, rather than a direct BDNF-boosting effect.
Mechanisms Compared
The two peptides share a structural motif — both contain Pro-Gly-Pro at the C-terminus — but their primary targets and clinical applications diverge meaningfully.
Semax acts principally on the BDNF-trkB axis and broadly on inflammatory gene expression in ischemic brain tissue. Its cognitive effects in animal models appear to be downstream of this neurotrophic and neuroprotective activity. Think of it as a compound that shores up the scaffolding of the brain under acute stress rather than sharpening processing in a healthy brain.
Selank acts principally at GABA receptors, with secondary effects on serotonin systems and enkephalin breakdown. Its anxiolytic activity is consistent enough across animal models that the mechanism is plausible, but the step from "reduces anxiety in stressed rats via GABA modulation" to "improves cognitive performance in healthy humans" requires human data that does not currently exist at FDA-recognized standards.
Both peptides modulate BDNF — a point that nootropic marketers tend to oversimplify. The nature of that modulation differs. Semax appears to increase BDNF in normal and ischemic conditions. Selank appears to normalize BDNF when it has been dysregulated by ethanol. These are different phenomena that should not be collapsed into a single "boosts BDNF" claim.
Evidence Quality: Russian vs. Western Standards
This is the section most vendor-written summaries skip. Russian regulatory approval is based on clinical trials conducted under Russian regulatory standards, which differ in several important ways from FDA or EMA requirements.
Russian clinical trials for drugs like Semax and Selank typically involved smaller sample sizes — often fewer than 100 patients — shorter follow-up periods, and less rigorous control for publication bias. They were conducted at a small number of state-affiliated institutes, raising questions about independence. Many were not registered in advance with a public trial registry, which is a standard requirement for FDA-accepted submissions because pre-registration prevents selective reporting.
This does not mean the research is fabricated or that the compounds do not work. It means the evidence has not been subjected to the adversarial scrutiny that FDA approval requires: independent replication by investigators without a financial or institutional stake in the outcome, conducted under good clinical practice guidelines that include pre-registration and transparent adverse event reporting.
No Semax RCT and no Selank RCT has been conducted under a US Investigational New Drug (IND) application. Neither compound appears in the FDA's drug database as an approved or investigational agent.
The three human cognition studies mentioned most often in nootropic forums for Semax are small Russian trials published in Russian-language journals, subsequently translated and indexed on PubMed. They are the best human data available. They are also not a substitute for Phase III data. The same applies to Selank's anxiety trial data.
Regulatory Status
| Region | Semax Status | Selank Status |
|---|---|---|
| Russia | Approved for stroke recovery, TBI, optic nerve disease | Approved for anxiety disorder, neurasthenia |
| United States | NOT FDA-approved for any indication | NOT FDA-approved for any indication |
| European Union | Not approved in any EU member state | Not approved in any EU member state |
| Grey market | Sold as "research peptide," not for human use | Sold as "research peptide," not for human use |
Russian approval means these compounds have passed Russian safety and efficacy review. It does not mean they meet the evidentiary standard required by the FDA or EMA. These are separate regulatory regimes with different requirements. A compound approved in Russia is not automatically recognized or permitted for human therapeutic use in the United States.
Sites selling Semax and Selank in Western countries typically label them "for research use only" or "not for human consumption." This labeling exists for a specific legal reason: it places the product outside the FDA's jurisdiction over drugs, supplements, and food, while allowing the sale to continue. It is not a safety endorsement. Purchasing these compounds online in the US exists in a legal grey zone, and the quality control of grey-market peptide synthesis is not subject to the manufacturing oversight that governs pharmaceutical drugs.
Side-by-Side Comparison
| Property | Semax | Selank |
|---|---|---|
| Origin | ACTH 4-10 fragment | Tuftsin analog (IgG fragment) |
| Structure | 7 amino acids (Met-Glu-His-Phe-Pro-Gly-Pro) | 7 amino acids (Thr-Lys-Pro-Arg-Pro-Gly-Pro) |
| Primary mechanism | BDNF upregulation, immunomodulation, anti-inflammatory | GABA allosteric modulation, serotonin and enkephalin effects |
| Russian indication | Stroke, TBI, cognitive impairment | Anxiety disorder, neurasthenia |
| FDA status | NOT approved | NOT approved |
| Main evidence base | Animal ischemia models, small Russian human trials | Animal anxiety models, small Russian human trials |
| BDNF effect | Increases BDNF (hippocampus, basal forebrain) | Normalizes dysregulated BDNF (stress, ethanol models) |
| Cognitive claim | Neuroprotection, memory enhancement | Anxiolytic, indirect cognitive benefit via stress reduction |
| Administration | Intranasal (clinical) | Intranasal (clinical) |
| Evidence in healthy humans | None at FDA-recognized standard | None at FDA-recognized standard |
| Grey-market availability | Yes, "research peptide" | Yes, "research peptide" |
Frequently Asked Questions
Can Semax or Selank improve cognition in healthy people?
There is no published, double-blind, placebo-controlled human trial demonstrating this for either compound in a healthy adult population. The animal data and the Russian clinical data suggest plausible mechanisms, but "plausible mechanism" and "demonstrated human benefit" are different things. Be skeptical of vendor claims that conflate them.
Is Selank safer than a benzodiazepine?
Animal data suggests Selank produces anxiolytic effects with lower sedation and no evidence of physical dependence in rodent models. That does not establish the same safety profile in humans. Benzodiazepines are FDA-approved and have decades of documented human pharmacokinetic and adverse event data. Selank has neither. Do not substitute Selank for a prescribed medication without physician involvement.
Are these peptides legal to buy in the US?
Purchasing them is not explicitly a criminal act for personal use, but selling them as human-use drugs without FDA approval is illegal. Grey-market sites circumvent this by labeling products "not for human consumption" or "research only." This is a legal sleight of hand, not a safety guarantee.
Do they stack well together?
Some biohackers combine them, citing complementary mechanisms — Semax for cognitive stimulation, Selank for anxiety reduction. No published trial has examined this combination. The interaction profile is entirely unknown.
What should someone with cognitive decline do instead?
See a neurologist or psychiatrist. Cognitive decline has identifiable causes — sleep disorders, thyroid dysfunction, B12 deficiency, depression, early-stage neurodegenerative disease — most of which respond to evidence-based treatment. Substituting experimental peptides for a proper workup is not a low-risk choice; it is a delay of diagnosis. For more context on evidence-backed cognitive strategies, read our guide to peptides for cognition and the foundational overview at what are peptides.
Actionable Takeaways
If you are considering Semax or Selank: Understand that you are self-experimenting with a compound that has no FDA-approved dosing, no independent quality control on the product you would receive, and a mechanism studied primarily in rodents. That is a significant unknown. The Russian clinical data is real but cannot substitute for Phase III evidence.
If you have a neurological condition: Semax is used in Russia for stroke recovery under physician supervision, with established dosing and monitoring. If a physician in a jurisdiction where it is approved recommends it, that conversation looks different than a grey-market online purchase. Those are not the same situation.
If your goal is anxiety reduction: There are compounds with substantially stronger human evidence — including SSRIs, buspirone, and structured therapy — that should be explored first with a qualified clinician. Selank's GABA mechanism is scientifically interesting. "Scientifically interesting" is not a clinical recommendation.
If you want to follow the Semax or Selank research: PubMed is searchable and open. The BMC Genomics ischemia study (PMID 24661604), the BDNF hippocampus study (PMID 16996037), and the Selank GABA modulation paper (PMID 30255741) are the best places to start. Read the limitations sections, not just the abstracts. For related reading on evidence-based cognitive support, see peptides for energy to understand how overlapping nootropic claims are made across this category.
Conclusion
Semax and Selank are not pseudoscience. They are compounds with real pharmacological mechanisms, genuine published research, and legitimate clinical use in Russia. They are also not FDA-approved drugs, not supported by the quality of evidence that US or EU regulators require, and not available in the West through any regulated pharmaceutical channel. The gap between "approved in Russia" and "safe and effective by FDA standards" is wide enough to matter for any decision about personal use.
If you experience neurological symptoms or significant anxiety, see a physician before experimenting with any unregulated compound. A delayed diagnosis is not a small risk.
The science on both peptides is worth watching. The grey-market products sold on the basis of that science are a different matter entirely.
This article is for informational purposes and not medical advice. Peptides, especially those marketed for therapeutic use, can interact with medications and health conditions. Consult a licensed physician before starting any supplement, particularly if you are pregnant, nursing, taking prescription medications, or managing a chronic condition.
